🟢 Liquidia Technologies is trading 44% up in pre-market after United Therapeutics settlement resolves six lawsuits

Liquidia Technologies is trading 43.77% up at $38.54 in pre-market on October 14, after its October 13 agreement with United Therapeutics resolved all six pending lawsuits.

• The settlement preserves uninterrupted YUTREPIA access for PAH patients; Liquidia will remove the PH-ILD indication and pay $380.7 million in net settlement payments.
• Preliminary, unaudited Q3 YUTREPIA sales were $222.7 million; cash was $396.1 million as of September 30. Coverage linked the after-hours surge to the settlement; modest broader-index gains did not explain the sharp rise.